



UNITED STATES PATENT AND TRADEMARK OFFICE

SK
UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/053,516	01/16/2002	Xianqiang Li	26757-710	1568
21971	7590	04/15/2004	EXAMINER	
WILSON SONSINI GOODRICH & ROSATI 650 PAGE MILL ROAD PALO ALTO, CA 943041050			TUNG, JOYCE	
		ART UNIT	PAPER NUMBER	
		1637		

DATE MAILED: 04/15/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No.	Applicant(s)
	10/053,516	LI ET AL.
	Examiner	Art Unit
	Joyce Tung	1637

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) Responsive to communication(s) filed on 22 January 2004.
- 2a) This action is **FINAL**. 2b) This action is non-final.
- 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) Claim(s) 1-17 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) Claim(s) _____ is/are allowed.
- 6) Claim(s) 1-17 is/are rejected.
- 7) Claim(s) _____ is/are objected to.
- 8) Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) The specification is objected to by the Examiner.
- 10) The drawing(s) filed on _____ is/are: a) accepted or b) objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) All b) Some * c) None of:
 1. Certified copies of the priority documents have been received.
 2. Certified copies of the priority documents have been received in Application No. _____.
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413) |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | Paper No(s)/Mail Date. _____ . |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)
Paper No(s)/Mail Date _____ . | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152) |
| | 6) <input type="checkbox"/> Other: _____ . |

DETAILED ACTION

The applicant's response (filed 1/22/2004) to the Office action has been entered.

Claims 1-17 are pending.

Continued Examination Under 37 CFR 1.114

1. A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 1/22/2004 has been entered.

2. Applicant's arguments in the response filed 1/22/2004 with respect to claims 1-17 have been considered but are moot in view of the new ground(s) of rejection.

Claim Rejections - 35 USC § 103

3. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to

consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

4. Claims 1-17 are rejected under 35 U.S.C. 103(a) as being unpatentable over Kain et al. (6,306,600, issued October 23, 2001) in view of Anderson et al. (6,548,249, issued April 15, 2003).

Kain et al. disclose a fusion protein comprising green fluorescent protein (GFP) as a reporter and short live protein, mouse ornithine decarboxylase (See column 2, lines 30-33) for studying protein degradation (See column 2, lines 13-18). The EGFP-MODC fusion protein can be used in drug screening. GFP fluorescence can be detected intracellularly without performing any additional steps (See column 4, lines 25-28). The invention is a method of assaying activation or deactivation of promoters or other transcriptional or translational elements with a transient fluorescent reporter protein, comprising the steps of transfecting cells with an expression vector comprising a fusion protein (See column 7, lines 66-67 and column 8, lines 1-11). The differences of the fluorescence intensity between cells expressing the fluorescent protein under different transcriptional or translational elements of interest is rapidly detected. Further, the transfected cells are treated with a compound of interest to determine the effect of the compound of interest on the transcriptional or translational elements. A change in fluorescence upon treatment of the cells with the compound of interest is also rapidly detected (See column 8, lines 11-22). The invention is also used to study cell lineage (See column 8, lines 24-25). The transfected cells as well as cycloheximide treated cells were analyzed for fluorescence intensity by FACS (See column 9, lines 19-35). It is suggested that a population of cells can be selected by different reporter signal intensities. The half

life of the fusion protein was determined by blocking protein synthesis with cycloheximide (See column 10, lines 32-35). The transfected cell line can be used for much analysis, for example, drug that inhibits protein degradation after the addition of cycloheximide (See column 13, lines 60-67). It is suggested that the drug is an agent, which affects the degradation rate of the protein.

Kain et al. do not disclose expressing a different fusion protein in each cell and under different growth conditions and that the selected population of cells contacted with a plurality of agents, which may affect protein degradation rates.

Anderson et al. disclose the invention related to the use of scaffold proteins, green fluorescent protein in fusion constructs with random and defined peptides and peptides libraries (See the Abstract). Each random peptide in the library is different (See column 2, lines 17-29). One of the random peptides is ornithine decarboxylase (See column 21, lines 10-13), which is short-lived fusion protein. The condition for fusion protein expression will vary with the choice of the expression vector and the host cell and will be easily ascertained by one skilled in the art through routine experimentation (See column 42, lines 40-44). It suggested that the cells expressing fusion protein will be grow under different growth conditions based upon the needs. The invention comprise introducing a molecular library of fusion nucleic acids encoding randomized peptides fused to scaffold into a plurality of cells. Each of the nucleic acids comprises a different nucleotide sequences encoding scaffold with a random peptide. The plurality of cells is then screened (See column 45, lines 64-67 and column 46, lines 1-5). The cells are isolated by FACS (See column 47, lines 50-55). A cell with an altered phenotype is detected, and the presence of fusion protein is verified to ensure that the peptide was expressed (See

column 47, lines 41-44). It is suggested that each cell has a different fusion protein. The screening methods of the invention may be useful to screen a large number of cell types under a wide variety of conditions (See column 49, lines 20-29).

One of ordinary skill in the art would have been motivated to modify the method of Kain et al. by expressing a different fusion protein in each cell within a library of cells, and contacting the selected population of cells with a plurality of agents which may affect protein degradation rates and under different growth condition as taught by Anderson et al.. The motivation is that the method of Anderson et al. allows the creation of a peptide library that is easily monitored, both for its presence within cells and its quantity and the peptides within or fused to a scaffold are being accessible for interaction with potential functional targets (See column 4, lines 52-56) and the screening methods of the invention may be useful to screen a large number of cell types under a wide variety of conditions (See column 49, lines 20-29). It would have been prima facie obvious to modify the method of Kain et al. by expressing a different fusion protein in each cell within a library of cells, and contacting the selected population of cells with a plurality of agents which may affect protein degradation rates and under different growth condition for screening the agents that affect protein degradation rates, monitoring the expression of short-live proteins under different growth conditions and screening the differences in short lived proteins expressed by first and second cell sample.

Summary

5. No claims are allowable.

Art Unit: 1637

6. Any inquiries concerning this communication or earlier communications from the examiner should be directed to Joyce Tung whose telephone number is (703) 305-7112.

The examiner can normally be reached on Monday-Friday from 8:00 AM-4:30 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Benzion can be reached at (703) 308-1119 on Monday-Friday from 10:00 AM-6:00 PM.

Any inquiries of a general nature or relating to the status of this application should be directed to the Chemical/Matrix receptionist whose telephone number is (703) 308-0196.

7. Papers related to this application may be submitted to Group 1600 by facsimile transmission. Papers should be faxed to Art Unit 1637 via the PTO Fax Center located in Crystal Mall 1 using (703) 305-3014 or 308-4242. The faxing of such papers must conform with the notice published in the Official Gazette, 1096 OG 30 (November 15, 1989).

Joyce Tung

April 6, 2004


KENNETH R. HORLICK, PH.D
PRIMARY EXAMINER

4/8/04